JCI The Journal of Clinical Investigation

The Glucose Metabolism of Patients with Malignant Disease and of Normal Subjects as Studied by Means of an Intravenous Glucose Tolerance Test

Paul A. Marks, Jonathan S. Bishop

J Clin Invest. 1957;36(2):254-264. https://doi.org/10.1172/JCI103419.

Research Article



Find the latest version:

https://jci.me/103419/pdf

THE GLUCOSE METABOLISM OF PATIENTS WITH MALIGNANT DISEASE AND OF NORMAL SUBJECTS AS STUDIED BY MEANS OF AN INTRAVENOUS GLUCOSE TOLERANCE TEST 1, 2

By PAUL A. MARKS AND JONATHAN S. BISHOP 8

(From the Medical Services of The Francis Delafield Hospital and The Presbyterian Hospital, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, N. Y.)

(Submitted for publication September 5, 1956; accepted October 4, 1956)

Since the observations of Freund (2) in 1885 of spontaneous hyperglycemia in patients with malignant disease, there has been speculation that an alteration in glucose metabolism is associated with neoplasia in man (3-18). There have been, however, relatively few studies designed specifically to test this possibility. Rohdenburg, Bernhard, and Krehbiel (5) and Edwards (6), with the advent of the oral glucose tolerance test, reported that a decrease in carbohydrate tolerance was a uniform finding in patients with cancer. Subsequent studies (7-18) did not confirm these reports, though several workers have found a high incidence of an abnormal glucose tolerance test in subjects with various types of neoplasms. These observations have been inconclusive with regard to establishing a relationship between the presence of uncomplicated neoplastic disease and an altered carbohydrate metabolism. A primary reason for the inconclusive nature of these studies is their lack of control of various factors known to decrease glucose tolerance. Certain of these factors, e.g., inadequate dietary intake, fever, infection, hepatic dysfunction and prolonged bed rest, are frequently present in patients with malignant disease.

This study was undertaken in a group of carefully selected patients with chronic leukemia, lymphoma, and clinically early epithelial neoplasms, and subjects without cancer, in an effort to determine whether a defect in glucose metabolism is associated with malignant tumors. It was found that, as a group, the patients with neoplastic disease had a significant decrease in the rate of disappearance of glucose from the blood following the intravenous injection of glucose. Carbohydrate metabolism was evaluated further in these subjects by calculation of the net rate of disappearance of glucose from the blood and the volume of distribution of glucose and by determination of the changes in serum inorganic phosphate and potassium concentrations during the glucose tolerance tests.

METHODS

Subjects studied

The control group consisted of 19 individuals without neoplastic disease, 7 males and 12 females, ranging in age from 29 to 65 years. The neoplastic group included 36 individuals, 14 males and 22 females, ranging in age from 36 to 70 years. There was no significant difference between the control and neoplastic groups with respect to age or body weight. Subjects 20 through 33 had clinically localized carcinoma, which was in all instances considered amenable to curative therapy. These individuals had no systemic symptoms. Carcinoma was suspected on the basis of a finding of a lump in the breast on physical examination, a positive Papanicoloau smear on routine cervical examination, or an abnormal shadow on routine chest x-ray. Subjects 34 through 54 had lymphoma or chronic leukemia. The diagnosis in each individual was established histologically (Tables I and II). All subjects were studied preoperatively, or prior to chemotherapy or radiotherapy.

The criteria for selection of individuals for study in both the control and patient group included: 1) no family history of diabetes mellitus, 2) full ambulation, 3) no weight change for at least six months prior to the study, 4) no obesity, 5) no evidence or history of any disorder known to affect carbohydrate metabolism, 6) no fever, 7) normal serum concentrations of sodium, potassium, chloride, carbon dioxide, non-protein nitrogen, alkaline phosphatase, cholesterol and cholesterol ester, and a normal cephalin flocculation, and 8) an adequate dietary intake.

¹A portion of the present data has been published previously in abstract form (1).

² This work was supported in part by a grant from The National Cancer Institute, U. S. Public Health Service.

⁸ Fellow of the American Cancer Society.

			Glucose concentration (mgm. %) (Time in minules)							Disap rate (%	Disappearance rate constant (%/min.)		Mean glucose concentration (mgm. %)		Net glucose disappearance‡ (mgm. %/min.)	
No.*	glucose†		;	16	24	32	40	48	56	64	Total	Increment	Total	Increment	Total	Increment
1	79	20	6	231	200	175	156	141	129	119	1.51	2.81	235	139	3.68	3.91
$\overline{2}$	64	21	9	192	185	153	115	96	87	80	2.30	4.62	223	112	5.12	5.19
3	88	28	88	240	188	164	124	92	76	73	2.89	4.36	180	111	5.20	4.85
4	80	- 30)4	244	200	176	148	120	92	86	2.20	3.75	209	120	4.60	4.50
5	100-98	20	53	222	202	179	164	151	140	125	1.31	3.10	200	89	2.62	2.76
6	86-88	28	34	198	135	110	87	64	60	59	3.47	7.96	132	66	4.58	5.25
7	75-76	19	8	191	164	144	120	106	96	89	1.78	3.22	158	80	2.81	2.58
8	68-66	25	60	216	175	148	125	109	98	77	2.30	4.08	183	103	4.21	4.20
<u>9</u>	88-85	18	8	176	152	131	122	108	104	99	1.56	3.96	206	81	3.21	3.21
10	92-90	27	5	243	198	176	161	147	134	122	1.51	3.15	209	105	3.16	3.31
11	83-83	17	5	156	138	128	117	110	95	83	1.33	3.22	160	62	2.12	2.00
12	89-94	26	4	208	176	145	121	110	92	86	2.16	5.10	185	76	5.00	3.88
13	82-87	18	8	156	122	104	92	92	90	87	2.01	6.42	143	43	3.73	3.58
14	73-72	18	0	172	155	141	128	117	110	102	1.31	2.78	151	74	2.36	2.49
15	83-81	23	1	192	147	123	108	97	78	70	2.08	6.30	208	67	4.83	4.52
16	81-70	24	0	230	193	174	158	137	134	110	1.59	2.90	199	113	3.16	3.28
17	92-88	25	8	212	188	175	160	140	132	111	1.61	2.78	187	104	2.98	2.86
18	78-82	21	0	186	160	145	131	114	94	80	1.58	3.15	165	80	2.74	2.62
19	84-85	25	0	168	142	115	104	90	87	82	3.15	6.03	142	73	4.88	4.03
Avera	ge 83	23	8	202	164	148	129	113	101	92	1.97	4.20	180	89	3.74	3.68
S.D.	8	3	8	28	26	23	23	22	22	18	.62	1.52	29	24	1.04	0.93

TABLE I Intravenous glucose tolerance test in control subjects

* Diagnoses: Cases 1-5, 9, 11-13, 16-19: Volunteers. Cases 6, 7, 10, 14, 15: Fibroadenoma of breast. Case 8: Cervical erosion.

† Where single value for fasting glucose is given, only one fasting blood sample was obtained.

Refer to text for definition of these terms and methods of calculating their values.

Procedures

All subjects were placed on a diet containing at least 225 grams of carbohydrate and 2400 calories daily for two weeks prior to study. Each individual, having fasted overnight for 14 hours, was kept completely at rest in an air conditioned room (temperature 78 to 81° F) for onehalf hour prior to and during the test. An indwelling Cournand-type needle was placed in an antecubital vein. After two fasting blood samples had been obtained over a period of approximately 20 minutes, a 30 per cent glucose solution in distilled water was injected into another vein. In control subjects, 1 through 11, and patients 20 through 27, and 34 through 42, twenty-five grams of glucose was administered from a syringe over a four-minute period. In all other individuals, the glucose was administered using a Bowman constant infusion pump over a three to five-minute period. This permitted a more accurate determination of the amount of glucose delivered (Table VI).

Venous blood specimens were withdrawn without stasis into heparinized syringes at eight minutes following the start of the glucose injection and subsequently every eight minutes for 64 minutes. Glucose concentration and, when performed, serum inorganic phosphate and serum potassium concentrations were determined in duplicate on each blood sample. The blood specimens were immediately iced and protein-free filtrates for the glucose analyses were promptly prepared at the bedside. Urine was collected during the 75 minutes following the injection of glucose for the determination of urinary glucose excretion during the test.

Ten patients had 2 or 3 repeat glucose tolerance tests performed (Table III). Six of these subjects were maintained on a constant carbohydrate and caloric intake on the metabolic ward during the interval between the studies. The remaining four individuals followed the prescribed diet on an outpatient basis during the period of observation.

Glucose was determined in duplicate by the Nelson modification of the Somogyi method (19, 20). Serum inorganic phosphorus determinations were made according to the method of Taussky and Shorr (21). Serum potassiums were determined using a flame photometer with an internal standard.

Analysis of glucose tolerance curves

Methods of analysis of the rapid intravenous glucose tolerance test have varied. In the present study, each glucose tolerance curve was graphically evaluated both by the method suggested by Conard, Franckson, Bastenie, Kestens, and Kovacs (22) and by the technique employed by Amatuzio, Stutzman, Vanderbilt, and Nesbitt (23). These two methods were chosen because (a) they provide methods which facilitate analyzing the glucose tolerance curve in terms of a single constant, (b) a large amount of normal data is available in the literature for these techniques, and (c) in the present study, by means of statistical analyses which will be presented below.

			Glucose concentration (mgm. %) (Time in minutes)							Disap rate o (%)	Disappearance rate constant (%/min.)		Mean glucose concentration‡ (mgm. %)		Net glucose disappearance‡ (mgm. %/min.)	
Subject No.*	r asting glucose†	8	16	24	32	40	48	56	64	Total	Increment	Total	Increment	Total	Increment	
20	84	237	215	183	169	163	152	145	129	0.75	1.84	222	99	1.67	1.82	
21	104	305	255	227	212	196	181	170		1.08	2.12	231	120	2.49	2.54	
22	90	324	260	220	196	172	152	141	112	1.51	2.89	231	127	3.49	3.67	
23	93	218	194	168	152	144	134	127	120	0.88	2.78	187	74	1.65	2.06	
24	9094	256	228	217	194	190	174	166	157	0.78	1.61	228	121	1.78	1.95	
25	82	322	268	228	180	166	140	108	84	2.02	3.07	221	138	4.47	4.23	
26	101–98	255	230	218	200	192	171	163	132	0.91	1.60	207	116	1.88	1.89	
27	96	309	260	233	212	182	170	157	142	1.22	2.43	244	133	2.98	3.23	
28	56-59	219	192	180	168	158	147	137	120	0.79	1.26	184	118	1.48	1.52	
29	84-86	342	296	272	240	218	200	183	166	1.25	2.02	270	177	2.97	3.15	
30	98-93	282	258	236	224	210	195	180	170	0.90	1.44	227	157	2.36	2.60	
31	119–115	312	288	270	250	228	218	206	195	0.94	1.61	269	130	2.56	2.11	
32	84-81	285	240	210	190	169	151	137	124	1.33	2.43	220	128	2.99	3.17	
33	80-81	309	264	231	209	192	176	162	150	1.17	2.06	243	149	2.91	3.13	
34	75	200	187	171	157	138	126	116	99	1.23	2.49	172	86	2.11	2.14	
35	86-88	242	192	178	156	143	132	116	98	1.15	2.71	171	80	1.97	2.17	
36	120	363	321	302	261	242	210	206	195	1.06	1.80	267	152	2.83	2.74	
37	90-86	204	180	169	160	147	135	128	112	0.94	2.19	174	79	1.64	1.73	
38	80	239	192	164	140	133	121	109	95	1.26	3.05	179	81	2.26	2.47	
39	110-114	239	224	212	204	199	192	180	170	0.51	1.27	213	99	1.09	1.26	
40	78–79	245	206	180	170	145	137	128	107	1.17	2.31	186	100	2.17	2.31	
41	108-106	282	257	242	226	205	200	185	176	0.80	1.85	342	99	2.73	1.83	
42	92	334	226	218	207	189	178	163	154	0.82	1.73	287	126	2.34	2.18	
43	110-106	252	238	225	212	201	191	183	175	0.67	1.57	237	115	1.61	1.83	
44	84-88	240	200	190	176	164	159	148	141	0.68	1.49	234	128	1.69	2.02	
45	92	196	164	146	142	112	110	90	86	1.26	4.62	173	52	2.24	2.48	
46	75–78	294	250	210	180	162	141	114	102	1.82	3.08	221	132	4.02	4.07	
47	7880	279	251	208	197	182	169	159	149	0.98	1.61	193	128	1.89	2.05	
48	65-68	185	171	152	138	123	118	101	92	1.15	2.39	154	82	1.58	1.75	
49	77-81	198	170	155	146	139	129	123	117	0.73	1.73	154	66	1.00	1.00	
50	78–74	311	244	185	157	124	107	96	87	2.36	5.22	218	106	5.76	6.20	
51	84-84	264	228	217	204	198	189	180	172	0.53	1.02	213	126	1.13	1.29	
52	87–89	192	177	165	153	145	137	131	119	0.75	1.76	169	62	1.41	1.22	
53	90-91	204	181	162	147	140	126	119	115	1.10	2.73	173	67	2.63	2.67	
54	87-89	246	218	194	184	166	152	141	129	1.12	2.28	196	101	2.27	2.36	
55	91-92	242	222	203	189	175	168	154	146	1.02	1.88	199	105	2.07	2.01	
Avera	ge 89	262	226	204	186	171	155	146	132	1.06	2.22	209	102	2.34	2.41	
S.D.	13	46	40	34	32	31	30	30	31	0.33	0.85	40	9	0.91	0.96	

 TABLE II

 Intravenous glucose tolerance tests in patients with neoplastic disease

* Diagnoses: Cases 20, 21, 24, 26–28, 30, 32, 33: Carcinoma of cervix, Stage I or II; Cases 22, 23, 29, 31: Carcinoma of breast; Case 25: Carcinoma of lung; Cases 39, 43, 49, 54, 55: Chronic myelogenous leukemia; Cases 34, 37, 53: Chronic lymphatic leukemia; Cases 35, 40–42, 44, 47: Hodgkins; Cases 46, 48, 50–52: Lymphosarcoma; Cases 36, 38, 45, 50: Reticulum cell sarcoma.

† Where single value for fasting glucose is given, only one fasting blood sample was obtained.

‡ Refer to text for definition of these items and methods of calculating their values.

they were found to provide good reproducibility in a given individual, and good discrimination between the control and neoplastic groups.

The intravenous glucose tolerance curve may be analyzed by plotting the log of the total blood glucose concentration against time to obtain a straight line (22). This relationship suggests that the rate of fall of blood glucose at any time is proportional to the total blood glucose value at that time.

Amatuzio and his co-workers (23) found that the plot of the log of the blood glucose value in excess of the initial fasting level against time was a straight line. These authors suggested, therefore, that the rate of fall of blood glucose at any time is proportional to the blood glucose concentration in excess of the fasting level at that time. An index of glucose tolerance may be obtained by plotting the data according to either of the above indicated methods and then applying the equation:

$$K = \frac{\log_{\bullet} 2}{t_{i}},$$

where in determining the fractional rate constant of disappearance of "total glucose" (K_b), $t_{1/3}$ is the time in minutes required for the total blood sugar value at any point to decline 50 per cent, or, in determining the fractional rate constant of disappearance of "increment glucose" (K_a), $t_{1/3}$ is the time in minutes required for the blood sugar value in excess of the fasting level at any point to decline 50 per cent.

Analysis of the present data, in accord with previously published studies (24, 25), indicates that neither of the methods (22, 23) mentioned above describes the entire glucose tolerance curve. Thus, the values of blood glucose at eight minutes and at times when the concentrations of blood glucose were below 25 mg. per cent in excess of the fasting value generally deviated from the simple exponential relationship. In this study, the blood sugar values between 16 minutes and 56 minutes following the beginning of the glucose injection were employed for graphic analysis. In addition, K_b and K_a were calculated, by the method of least squares, for each glucose tolerance test.⁴ The K values as determined 1) by this calculation and 2) by free-hand graphic analysis did not differ significantly, as shown by comparison of the means of the two paired samples.

The reliability of K_{\bullet} and K_{\bullet} in analysis of the present glucose tolerance data was further evaluated by two types of statistical analysis. First, employing the data obtained in repeat determinations in ten patients (Table III), analysis of variance revealed that both K_{\bullet} and K_{\bullet} showed

⁴ In actual practice, the constants were calculated in terms of the log to the base 10 and in terms of 8-minute periods. The constants (C) calculated in this manner were related to K_b or K_a by the equation:

a very small variation between repeat determinations in the same individual relative to the variation between individuals (Table IV). Amatuzio, Stutzman, Vanderbilt, and Nesbitt (23) have shown by duplicate tests in normal individuals that K_a is reproducible. Recently, Duncan (24) has demonstrated the reproducibility of both K_a and K_b in normal individuals. Secondly, employing the initial glucose tolerance test in each of the entire group of control and patient subjects, analysis of variance revealed that both K_b and K_a distinguished significantly between these groups (Table V). Furthermore, the discrimination between the neoplastic and normal group was equally good whether K_b or K_a was employed in analysis of the data (Table V).

It should be noted that the two methods employed in the analysis of the intravenous glucose tolerance curves are empirical and suggest different and mutually exclusive assumptions about the mechanisms controlling the rate of glucose disappearance. The present data indicate that while neither method is a completely accurate description of blood glucose disappearance, both fit the data sufficiently closely to provide good means of assessing glucose tolerance.

Net rate of disappearance of glucose. K_b and K_a provide a value for the fractional rate constant of glucose

Subject		Fosting				Disappearance rate constant (%/min.)						
No.	Date	glucose*	8	16	24	32	40	48	56	64	Total	Increment
41	6/22	108–106	282	257	242	226	205	200	185	176	0.80	1.85
	7/8	114–120	283	258	241	224	210	198	188	180	0.84	1.76
42	4/15	92	334	226	218	207	189	178	163	154	0.82	1.73
	4/21	96–100	276	231	196	186	187	174	161	150	0.82	1.87
43	5/6	110–106	252	238	225	212	201	191	183	175	0.67	1.57
	5/12	115–109	320	271	257	222	217	200	190	176	0.78	1.80
	5/19	118	278	258	241	226	212	201	197	185	0.76	1.60
44	7/6	86–86	240	200	190	176	164	159	148	141	0.68	1.49
	9/8	78–80	197	185	168	160	149	144	136	128	0.63	1.54
47	9/1	78–80	279	251	208	197	182	169	159	149	0.98	1.61
	1/12	86–84	300	288	256	233	215	199	184	170	1.02	1.61
48	9/12	65–68	185 -	171	152	138	123	118	101	92	1.15	2.39
	11/18	79–78	232	200	179	158	142	130	120	111	1.25	2.51
49	9/23	77–81	198	170	155	146	139	129	123	117	0.73	1.73
	1/12	82–90	264	218	201	191	180	168	158	147	0.80	1.57
52	11/21	87–89	192	177	165	153	145	137	131	121	0.75	1.76
	1/3	86–85	196	189	164	154	142	138	125	118	0.79	1.86
54	2/23	81–89	246	218	194	184	166	152	141	129	1.12	2.28
	3/1	79–82	228	192	177	162	151	136	121	112	1.12	2.15
	3/8	80–81	240	204	192	168	156	143	132	118	1.19	2.28
55	5/14	91–92	242	222	203	189	175	168	154	146	1.02	1.88
	5/24	90–92	264	240	222	206	184	175	164	150	1.02	2.01

TABLE III Rebeat intravenous glucose tolerance tests in patients with neoplastic disease

* Where a single value for fasting glucose is given, only one fasting blood sample was obtained.

TABLE IV
Analysis of variance of indices of repeat glucose tolerance tests in ten patients with neoplastic disease

D	Total index	Increment index		
of freedom	Sum of squares	Sum of squares		
9	.09951	.57087		
10	.00263	.02477		
19	.10215 41.92	.59564 25.61		
	Degrees of freedom 9 10 19	Degrees of freedom Total index Sum of squares 9 .09951 10 .00263 19 .10215 41.92		

*F _	Sum of Squares Between Individuals	v 10	3
· r ==	Sum of Squares Within Individuals	<u>^ </u>	÷٠,

For the number of degrees of freedom present in this table, an F value greater than 4.95 would give a probability less than 0.01.

disappearance, *i.e.*, the per cent of glucose disappearing from the blood per minute. In an effort to evaluate the net amount of glucose disappearing from the blood, an estimate was made of the mean net rate of disappearance of glucose, i.e., the milligrams of glucose disappearing per unit volume of blood per minute. The term net is used to indicate that this value represents the resultant of those reactions removing glucose from the blood and those reactions delivering glucose to the blood. In order to obtain the mean net rate of disappearance of "total glucose" from the blood per minute (G.D.,), the average "total glucose" concentration was multiplied by the rate constant K_b . The mean net rate of disappearance of "increment glucose" from the blood (G.D.a) was derived by multiplying K_a by the mean glucose concentration in excess of the fasting level.⁵ All values for net rate of disappearance of glucose, in subjects receiving other than 25 gm. of glucose, were corrected to this dose. The value obtained for mean net rate of disappearance of glucose is

⁵ The value for the average "total glucose" concentration was obtained by the equation:

$$\overline{G}_{b} = \frac{G_{o}(1 - e^{-K_{b}t})}{t \ K_{b}},$$

where \overline{G}_b is the average "total glucose" concentration in mgm. per 100 cc.; G_o is the total blood glucose concentration in mgm. per 100 cc. at zero time; t is the time interval in minutes during which the fractional rate of "total glucose" disappearance is constant.

The value for the average "increment glucose" concentration was obtained by the equation:

$$\overline{G}_{a} = \frac{(G_{o} - G_{f})(1 - e^{-K_{a}t})}{t K_{a}}$$

where \overline{G}_{a} is the average "increment glucose" concentration in mgm. per 100 cc.; G_{t} is the fasting blood glucose concentration in mgm. per 100 cc.; t is the time interval in minutes during which the fractional rate of "increment glucose" disappearance is constant. defined by the method employed in its calculation. It is used in this study only for the purpose of comparing the control and neoplastic groups with respect to this parameter. The value for G.D._b would be expected to be equal to the value for G.D._a if both a plot of the log of the "total glucose" concentration against time and a plot of the log of the "increment glucose" concentration against time represent good approximations of a straight line.

Estimation of volume of distribution of glucose. An estimate of the volume of distribution of glucose (EVG) was obtained in those subjects in whom the glucose was given using a constant infusion pump to permit an accurate determination of the volume of glucose solution injected. The EVG was calculated by dividing the amount of glucose injected (mgm.) by the glucose concentration in excess of the fasting value (mgm. per 100 cc.) at the end of injection. This glucose concentration was determined by extrapolating to the end of the injection period the linear plot of the log of the glucose concentration in excess of the fasting level between 16 and 56 minutes following the injections. The values for blood sugar concentration prior to 16 minutes generally fell above this line and were not employed in this graphic analysis to reduce the error due to mixing. It is recognized that this calculation is not free from objection, particularly when applied to metabolizable substances. Nevertheless, it is assumed that these errors will be similar in both control and neoplastic subjects.

RESULTS

The data obtained from intravenous glucose tolerance tests in 19 control subjects and 36 patients with neoplastic diseases are presented in Tables I and II. The diagnosis of each subject is indicated in these tables.

Fractional rate constant of glucose disappearance

The fractional rate of "total glucose" disappearance (K_b) for the control group was 1.97 ±

TABLE V Analysis of variance comparing the glucose tolerance tests in control subjects and patients with neoplastic disease

	Dograad	Total blood sugar index	Increment blood sugar index
	of	Sum of	Sum of
	freedom	squares	squares
Between groups	1	.64261	10.38503
Within groups	54	1.66644	27.77842
Total	55	2.30905	38.16345
F*		20.82	20.18

* F = $\frac{\text{Sum of Squares Between Groups}}{\text{Sum of Squares Within Groups}} \times \frac{54}{1}$

For the number of degrees of freedom present in this table, an F value greater than 7.12 would give a probability less than 0.01.



FIG. 1. THE AVERAGE CURVES OF TOTAL BLOOD GLU-COSE CONCENTRATION AGAINST TIME ARE PLOTTED FOR THE CONTROL (LIGHT SOLID LINE) AND PATIENT (HEAVY SOLID LINE) GROUPS AND THE AVERAGE CURVES OF THE BLOOD SUGAR CONCENTRATION IN EXCESS OF THE FASTING LEVEL AGAINST TIME ARE PLOTTED FOR THE CONTROL (LIGHT BROKEN LINE) AND PATIENT (HEAVY BROKEN LINE) GROUPS

The fractional rate of disappearance of "total glucose" (K_b) and the fractional rate of disappearance of "increment glucose" (K_b) are indicated in per cent per minute.

0.62 per cent per minute.⁶ The K_b for the neoplastic group was 1.06 ± 0.33 per cent per minute. The fractional rate of "increment glucose" disappearance (K_a) in the control group averaged 4.20 ± 1.52 per cent per minute. The neoplastic group had a K_a of 2.22 ± 0.85 per cent per minute. The difference between the means for both K_a and K_b were statistically significant ⁷ (Figure 1). Examination of Tables I and II will reveal that K_b in five subjects with neoplastic disease and K_a in six of these patients fell within the rangeof values for the control series.

The data for the control subjects are in general agreement with previous results obtained using the type of intravenous glucose tolerance test employed in this study. In 60 normal subjects reported by Lozner, Winkler, Taylor, and Peters (26), the K_b was 1.96 ± 0.30 per cent per minute and the K_a was 3.57 ± 0.37 per cent per minute. Amatuzio, Stutzman, Vanderbilt, and Nesbitt (23) reported data on 70 control individuals with a K_b

of 1.34 ± 0.27 per cent per minute and a K_a of 3.71 ± 0.40 per cent per minute. An average K_b of 1.52 ± 0.23 per cent per minute has been observed in 20 normal subjects (22). In 20 normal persons, Duncan (24) found a K_b of 1.37 ± 0.22 per cent per minute and a K_a of 3.68 ± 0.40 per cent per minute.

Blood sugar values

The fasting blood sugar for the control series was 83 ± 8 mgm. per cent and for the neoplastic group 89 ± 13 mgm. per cent (Tables I and II). The difference between these means was not statistically significant. Four patients with neoplastic disease did have fasting blood sugars in excess of 100 mgm. per cent, which was the upper value for the range of fasting blood sugar levels in the control group.

The average blood sugar values for the control and neoplastic groups at 8 and 16 minutes following glucose administration were not significantly different. The mean blood sugar concentrations at subsequent sampling times, *i.e.*, 24, 32, 40, 56 and 64 minutes, following glucose administration were significantly higher in the patients with neoplastic disease than in the control individuals (Tables I and II).

Urinary glucose excretion during the 75 minutes following the intravenous administration of glucose was determined in 14 control individuals and 22 patients. Urinary glucose excretion amounted to 0.8 ± 0.3 gm. during the 75-minute period in control individuals and 0.6 ± 0.3 gm. during the 75-minute period in the neoplastic group. There was no significant difference between these means.

Net rate of disappearance of glucose

The mean "total glucose" concentration (\bar{G}_b) was 180 ± 29 mgm. per cent in the control individuals and 209 ± 40 mgm. per cent in the neoplastic group. In the control group, the net rate of disappearance of "total glucose" from the blood $(G.D._b)$ was 3.74 ± 1.04 mgm. per 100 cc. per minute compared with a value of 2.34 ± 0.91 mgm. per 100 cc. per minute for the individuals with neoplastic disease (Tables I and II). The difference between the mean G.D._b and the difference

⁶ Average values are given with one standard deviation.

⁷A significant difference between the means was taken to be a difference of at least 3.2 times the standard deviation of the difference between means (p < .01).

	Control	subjects			Neoplastic	subjects	
Subject No.	Glucose administered (gm.)	V (liters)	V (% of BW)	Subject No.*	Glucose administered (gm.)	V (liters)	V (% of BW)
10 12 13 14 15 16 17 18 19	25.0 19.9 19.3 21.0 23.4 25.0 25.3 23.7 22.9	11.9 10.5 13.3 15.6 10.6 12.1 15.8 14.8 11.8	18.3 16.1 15.8 25.5 17.8 17.5 26.4 21.2 16.6	28 29 30 31 32 33 43B C 44B 45	24.4 28.5 21.7 24.8 24.4 24.4 24.6 24.6 24.6 23.7 24.2	11.8 9.2 11.0 11.3 11.1 10.2 16.4 16.2 17.2	20.7 19.7 17.8 17.4 23.5 17.9 26.6 26.3 22.8 19.1
Average S.D.	22.8	12.9 1.8	19.5 3.8	45 47B 48A B 49A 50 51 52A B 53 54A B C 55A B	24.2 25.0 28.2 24.0 28.3 25.1 22.4 25.0 22.4 23.4 17.1 24.2 24.2 24.2 25.3 24.6 24.0	17.0 10.8 16.8 17.5 14.5 15.5 7.6 15.7 15.5 12.8 16.1 15.4 15.2 13.3 14.5	19.1 18.5 21.4 22.7 25.3 26.6 12.0 26.4 23.8 25.8 17.3 25.5 24.4 24.1 21.8 21.7
				Average S.D.	24.3	13.2 3.0	21.0 3.8

 TABLE VI

 Estimated glucose volume of distribution in control and neoplastic subjects

* Letters refer to repeat determinations at time of repeat glucose tolerance tests (Table III).

between the average G_b for the control and patient groups were statistically significant.

The mean "increment glucose" concentration (\bar{G}_{*}) for the control subjects had a value of 89 ± 24 mgm. per cent compared with 102 ± 9 mgm. per cent for the neoplastic patients. Net rate of disappearance of "increment glucose" (G.D.a) was 3.68 ± 0.93 mgm. per 100 cc. per minute for the control subjects and 2.41 ± 0.96 mgm. per 100 cc. per minute for the patients with neoplastic disease. The difference between the mean G.D.a was significant, though there was no significant difference between the average values for Ga for the control and patient groups. There is close agreement between the values for G.D., and for G.D.a in both the control and neoplastic groups as predicted from the mathematical considerations indicated in the method section.

Examination of Tables I and II will reveal that G.D._b in 19 patients with malignant disease and G.D._a in 24 of these subjects fell within the range of values for the control group.

Estimated volume of distribution of glucose

Estimation of the volume of distribution of glucose (EVG) (Table VI) in control subjects yielded a value of 12.9 ± 1.8 liters or 19.5 ± 3.8 per cent of body weight, and in the neoplastic group a value of 13.2 ± 3.0 liters or 21.0 ± 3.8 per cent of body weight. These averages revealed that the EVG did not differ significantly between the two groups.

The values for EVG in the present study are in accord with previous findings. Jokipii and Turpeinen (27), using a 60-minute constant glucose infusion technique, reported a volume of distribution of glucose that averaged 17.0 per cent of body weight. One method (28), involving a single injection of carbon 14 labelled glucose, yielded an average volume of distribution of glucose of 24 per cent of body weight. Employing the same method as used in the present study, Dominguez (29) reported an average value of 19.0 per cent of body weight and Conard (30) found a mean of 24.3 per cent of body weight for the volume of distribution of glucose.

Serum phosphate and serum potassium concentration

The fasting serum inorganic phosphate level in the control group was 3.19 ± 0.36 mgm. per cent compared with a value of 3.61 ± 0.48 mgm. per cent for the patients with neoplastic disease. The difference between these means was statistically significant. The fasting serum potassium concentration had a value of 4.34 ± 0.32 mEq. per liter in the control subjects and 4.45 ± 0.34 mEq. per liter in the neoplastic individuals. These means did not differ significantly (Table VIII).

Most investigators consider the maximum fall in serum inorganic phosphate level and the maximum fall in serum potassium concentration as the important determinations in terms of reflecting glucose utilization, and the present data were analyzed from this standpoint. The maximum fall in serum inorganic phosphate in the control group was 0.67 ± 0.19 mgm. per cent or 22.0 ± 6.2 per cent of the fasting level. In the neoplastic subjects, the maximum decrease in serum inorganic phosphate was 0.61 ± 0.24 mgm. per cent or 16.7 ± 5.7 per cent of the fasting concentration. The difference between the mean values for the maximum fall of serum phosphate expressed in absolute terms was not significant. However, when the fall in serum phosphate concentration was expressed as a per cent of the fasting level, the difference between the means was of borderline significance. After a rapid injection of 25 gm. of glucose, Wertheim, Eurman, and Kalinsky (31) found a maximum fall in normals of $0.58 \pm$

TABLE VII

Serum inorganic phosphorus (mgm. %) and potassium (mEg./L.) concentrations during intravenous glucose tolerance tests

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			C	ontrol subje	cts					N	eoplastic sul	ojects		
		Ser	Serum phosphate			im potas	ium		Serum phosphate			Serum potassium		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Subject No.	Fasting	Max. decrease	% Decrease	Fasting	Max. decrease	% Decrease	Subject No.	Fasting	Max. decrease	% Decrease	Fasting	Max. decrease	% Decrease
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1	3.53	0.93	26.4	5.00	0.88	17.6	20	3.30	0.60	18.2	3.63	0.44	12.1
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2	3.30	0.31	9.4	3.78	0.08	21.2	21	3.71	0.52	14.0			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	3	3.38	0.90	26.8	4.23	0.15	3.5	22	3.66	1.06	28.9	4.25	0.63	14.8
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	4	2.75	0.65	23.6	4.72	0.30	6.4	23	3.98	0.48	12.1	4.56	0.21	4.6
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	5	3.25	0.61	18.8	4.60	0.87	18.9	24	3.82	0.55	14.4	4.27	1.07	25.1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	6	2.67	0.88	33.0	4.19	0.33	7.9	25	4.05	0.85	21.0			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7	2.83	0.83	29.4	4.06	0.50	12.3	26	3.15	0.65	20.6			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	8	3.47	0.93	26.8	3,98	0.49	12.3	27	2.87	0.54	18.8	4.30	0.40	9.3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9	3.60	0.80	22.2	4.34	0.12	2.8	28	4.42	0.77	17.4	4.68	0.62	132
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	10	3.62	0.73	20.2	4.49	0.59	13.1	29	3.45	0.53	15.4	4 33	0.23	5 3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	11	2.73	0.61	22.4	4.46	0.24	5.4	30	3.54	0.76	21.5	1.00	0.20	0.0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	12	2.69	0.49	18.2	4.20	0.33	7.9	31	3 28	0.37	11.3	4 60	0.55	12.0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	13	3.27	0.54	16.5				32	4 05	0.00	22.2	4.00	0.00	12.0
Aver. 3.19 0.6722.0 4.34 0.4110.8 35 3.10 0.29 9.3 4.14 0.63 15.15 S.D.0.360.196.20.320.28 5.9 37 3.14 0.30 9.6 38 3.77 0.88 23.3 4.14 0.51 12.3 39 4.21 1.14 27.1 5.15 1.33 25.4 40 3.85 0.95 24.6 41 3.60 0.50 13.9 4.79 0.21 4.4 42 3.95 0.55 13.9 4.666 0.68 14.4 43 4.10 0.52 12.7 3.92 0.44 11.3 443 4.10 0.52 12.7 3.92 0.44 11.4 443 4.10 0.52 12.7 3.92 0.44 11.4 443 4.10 0.52 12.7 3.92 0.44 11.4 444 3.87 0.58 15.0 4.96 0.48 8.3 45 4.43 0.33 7.4 47 4.20 1.06 25.2 4.16 0.37 8.9 49 4.03 0.52 12.9 50 3.19 0.54 16.9 52 3.09 0.42 13.6 53 3.40 0.60 17.6 57 0.34 0.32 7.9	14	3.62	0.52	14.4				34	3 35	0.60	17 0	4 40	0 50	134
Aver. 3.19 0.67 22.0 4.34 0.41 10.8 36 2.26 0.32 16.8 4.18 0.89 21.3 S.D. 0.36 0.19 6.2 0.32 0.28 5.9 37 3.14 0.30 9.6 38 3.77 0.88 23.3 4.14 0.51 12.3 39 4.21 1.14 27.1 5.15 1.33 25.4 40 3.85 0.95 24.6 41 3.60 0.50 13.9 4.79 0.21 4.4 42 3.95 0.55 13.9 4.66 0.68 14.0 43 4.10 0.52 12.7 3.92 0.44 11.2 44 3.87 0.58 15.0 4.96 0.48 8.3 45 4.43 0.33 7.4 47 4.20 1.06 25.2 4.16 0.37 8.9 49 4.03 0.52 12.9 50 3.19 0.54 16.9 52 3.09 0.42 13.6 53 3.40 0.60 17.6 53 3.40 0.60 17.6 4.45 0.59 13.4 $5.D$ 0.48 0.24 5.7 0.34 0.32 7.9								35	3 10	0.00	03	1.10	0.57	15.4
S.D. 0.36 0.19 6.2 0.32 0.28 5.9 37 3.14 0.30 9.6 38 3.77 0.88 23.3 4.14 0.51 12. 39 4.21 1.14 27.1 5.15 1.33 25.3 40 3.85 0.95 24.6 41 3.60 0.50 13.9 4.79 0.21 4.4 42 3.95 0.55 13.9 4.66 0.68 14.0 43 4.10 0.52 12.7 3.92 0.44 11.3 44 3.87 0.58 15.0 4.96 0.48 8.3 45 4.43 0.33 7.4 47 4.20 1.06 25.2 4.16 0.37 8.9 48 3.78 0.18 4.8 5.10 0.79 15.3 49 4.03 0.52 12.9 50 3.19 0.54 16.9 52 3.09 0.42 13.6 53 3.40 0.60 17.6 Aver. 3.61 0.61 16.7 4.45 0.59 13.3 S.D. 0.48 0.24 5.7 0.34 0.32 7.4 13.5 13.5 13.5 13.5 13.5 13.5 13.5 13.5	Aver.	3.19	0.67	22.0	4.34	0.41	10.8	36	2.26	0.38	16.8	4 18	0.80	21.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	S.D.	0.36	0.19	62	0.32	0.28	50	37	3 14	0.00	10.0	4.10	0.09	21.4
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				0.2	0.02	0.20	5.7	38	3 77	0.30	22.2	4 14	0 51	12 2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								30	A 21	1 14	23.3	5 15	1 22	25.0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								40	2 95	0.05	21.1	5.15	1.55	23.0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$					·			41	3.60	0.95	12.0	4 70	0.21	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								41	2.00	0.50	13.9	4.19	0.21	4.4
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								44	3.93	0.33	13.9	4.00	0.08	14.0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								43	4.10	0.52	12.7	3.92	0.44	11.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								44	3.01	0.38	15.0	4.90	0.48	8.3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								43	4.43	0.33	1.4			~ ~
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								4/	4.20	1.00	25.2	4.10	0.37	8.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								48	3.78	0.18	4.8	5.10	0.79	15.5
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								49	4.03	0.52	12.9			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$								50	3.19	0.54	16.9			
53 3.40 0.60 17.6 Aver. 3.61 0.61 16.7 4.45 0.59 13. S.D. 0.48 0.24 5.7 0.34 0.32 7.4								52	3.09	0.42	13.6			
Aver. 3.61 0.61 16.7 4.45 0.59 13. S.D. 0.48 0.24 5.7 0.34 0.32 7.1								53	3.40	0.60	17.6			
S.D. 0.48 0.24 5.7 0.34 0.32 7.1								Aver.	3.61	0.61	16.7	4.45	0.59	13.5
								S.D.	0.48	0.24	5.7	0.34	0.32	7.5

0.24 mgm. per cent or 16.8 ± 5.9 per cent of the fasting value, and Lazarus, Volk, Jacobi, and Gilady (32) reported a mean maximum fall in normals of 14.2 per cent (10 to 22.5 per cent). These changes are more comparable to the findings in the patient group than in the normal individuals of the present study. It should be noted that in previous reports as well as in the present data, the range of values for maximum fall in serum inorganic phosphate is large.

The serum potassium concentration had a maximum fall of 0.41 ± 0.28 mEq. per L. or 10.8 ± 5.9 per cent of the fasting level in the control individuals. In the patient group, the maximum decrease in serum potassium was 0.59 ± 0.32 mEq. per L. or 13.5 ± 7.5 per cent of the fasting concentration. There was no statistically significant difference between the mean values for maximum fall, expressed in absolute or relative terms, in serum potassium concentration.

DISCUSSION

A decrease in glucose tolerance, as indicated by a slower fractional rate of disappearance of blood glucose, was found to be associated with the presence of malignant disease. The fasting blood sugar was within the normal range in these subjects. The group of patients studied included individuals with lymphoma, chronic leukemia, and clinically localized carcinoma of the cervix, and carcinoma of the breast. These individuals were carefully selected to exclude various other factors known to impair carbohydrate metabolism.

The slower fractional rate of disappearance of glucose in the patients with malignant disease was associated with a higher mean blood sugar concentration following the intravenous administration of glucose. The question arises, in view of these findings, as to whether the net amount of glucose disappearing from the blood in the neoplastic group differed from the control subjects. The mean value for the net rate of disappearance of glucose was significantly lower in the patients compared with the control group. However, in the patient group, a normal net rate of disappearance of glucose was more frequently observed than a normal fractional rate of disappearance of glucose. There was no difference in the estimated volume of distribution of glucose between the patients and the control individuals. These calculated values derived from the disappearance curve of glucose indicate that in certain neoplastic subjects, despite a decreased fractional rate of disappearance of glucose, the persistence of blood glucose concentrations at significantly higher levels than in normal subjects may be associated with an approximately normal net rate of disappearance of glucose. A possible explanation of these findings is that net hepatic glucose output during the hyperglycemic phase is greater in the patients than in the control individuals and contributes to maintaining the higher blood glucose concentration. This explanation does not exclude a concomitant decrease in tissue glucose utilization in these patients.

The present data do not permit conclusions as to the mechanism of the decrease in glucose tolerance. A slower fractional rate of disappearance of glucose, whether or not associated with a decreased net rate of disappearance of glucose, might result from an alteration in hepatic glucose metabolism, a decrease in peripheral utilization, or a disturbance in both of these metabolic processes.

Peripheral glucose utilization has been found to be associated with a fall in serum inorganic phosphate following glucose administration (33, 34). A decrease in serum potassium concentration has also been reported to parallel glucose utilization (35). No statistically significant difference was observed between the control and patient groups with reference to the maximum fall in the absolute concentration of serum inorganic phosphate or serum potassium. The mean fasting serum inorganic phosphate concentration in the patients with malignant disease was higher than in the control subjects. The maximum fall in serum inorganic phosphate expressed as per cent of the fasting level was smaller in the patient group than in the control individuals. It should be noted that in the patients with malignant disease, the maximum decrease in serum inorganic phosphate concentration and in serum potassium concentration was found to be variable, and in any given individual the magnitude of fall of these two ions did not parallel each other. The meaning of these findings in terms of glucose metabolism is not apparent.

The fact that the decrease in glucose tolerance

was associated with localized carcinoma, small in size relative to total body mass, would make it unlikely that, in these patients at least, the decreased rate of disappearance of glucose was attributable to the carbohydrate metabolism of the tumor. Indeed, Cori and Cori (36) demonstrated that tumor in vivo had an increased rate of glycolysis. It would appear that the defect in glucose metabolism reflects alterations in host tissue metabolism associated with the presence of the neoplastic process. In experimental animals, there are several reports of defects in enzyme activity (37), including enzymes involved in carbohydrate metabolism (38), of tissues of the tumorbearing host.

There are many studies on the incidence of cancer in diabetes mellitus (39). In general, these reports found that cancer occurs more frequently than expected in diabetics. The pertinence of this finding, if real, to the present data cannot be evaluated on the basis of available knowledge. The possibility does exist that the decrease in glucose tolerance in patients with malignant disease may reflect latent diabetes mellitus.

It should be emphasized that the defect in carbohydrate metabolism, as measured by the intravenous glucose tolerance test, is not at all specific. A decrease in glucose tolerance has been observed in a wide variety of conditions in addition to diabetes mellitus, such as endocrine disorders, hepatic disease, malnutrition, infectious diseases, neuropsychiatric disorders, renal disease and obesity. None of these conditions existed in the present group of patients with neoplastic disease. Thus, this defect in glucose metabolism can be considered of no diagnostic value; however, its definition may shed some light on the metabolic alterations associated with neoplasia, as well as other conditions in which a decreased glucose tolerance may be present.

SUMMARY

1. Intravenous glucose tolerance tests were performed in 36 carefully selected patients with chronic leukemia, lymphoma, and clinically early epithelial neoplasms, and in 19 subjects without cancer.

2. In analyzing the glucose tolerance curves, plotting either the log of the total blood sugar con-

centration against time, or the log of the blood sugar concentration in excess of the fasting value against time, provided an equally good index of glucose tolerance.

3. The patients with malignant disease compared with the control subjects had a significantly decreased fractional rate of disappearance of glucose and a significantly lower net rate of disappearance of glucose.

4. The fasting blood sugar concentration of the control and neoplastic groups did not differ significantly.

5. No significant difference in the estimated volume distribution of glucose was found between the two groups.

6. In the patients with malignant disease, the fasting serum inorganic phosphate concentration was significantly greater and the maximum per cent fall in inorganic phosphate was significantly less than in the control individuals. No significant difference was observed in the fall in serum potassium concentration between the two groups.

ACKNOWLEDGMENT

The authors are indebted to Prof. John Fertig for his assistance in the statistical analysis of the present data. We are grateful to Miss Mae D'Orlando, R.N., Chief Nurse on the Metabolic Unit, for her assistance in the patient studies, and to Mrs. Ellen Zablow for her technical assistance.

REFERENCES

- Marks, P. A., and Bishop, J., Glucose metabolism in human subjects with neoplastic diseases. J. Clin. Invest., 1956, 35, 722.
- Freund, E., Zur Diagnose des Carcinoms. Vorläufige Mittheilung. Wien. med. Bl., 1885, 8, 267.
- Tuffier, Diabète et néoplasmes. Arch. gén. de méd., 1888, 2, 129.
- Trinkler, N., Ueber die diagnostische Verwertung des Gehaltes an Zucker und reducirender Substanz im Blute vom Menschen bei verschiedenen Krankheiten. Zentralbl. f.d. Med. Wissensch., 1890, 28, 498.
- Rohdenburg, G. L., Bernhard, A., and Krehbiel, O., Sugar tolerance in cancer. J. A. M. A., 1919, 72, 1528.
- 6. Edwards, S., Blood sugar tolerance in cancer. J. Indiana M. A., 1919, 12, 296.
- Theis, R. C., and Stone, W. S., A study of the chemical composition of the blood in cancer. J. Cancer Research, 1919, 4, 349.

- Williams, J. R., with the collaboration of Humphreys, E. M., Clinical significance of blood sugar in nephritis and other diseases. Arch. Int. Med., 1919, 23, 537.
- Friedenwald, J., and Grove, G. H., The blood-sugar tolerance test as an aid in the diagnosis of gastrointestinal cancer. Am. J. M. Sc., 1920, 160, 313.
- Langston, W., Glucose tolerance test. J. Lab. & Clin. Med., 1922, 7, 293.
- Kelly, T. C., Blood-sugar retention in carcinoma. Am. J. M. Sc., 1925, 169, 216.
- Slosse, and Reding, Études des altérations humorales dans le cancer et le précancer. Le Cancer, 1927, 4, 442.
- Jackson, D., Carbohydrate metabolism in cancer. Texas State J. Med., 1929, 24, 622.
- D'Halluin, M., Cancer, glycémie expérimentale, radiations. Bull. et mém. Soc. de Radiol. méd. de France, 1930, 18, 249.
- Chatain, A., Contribution à l'étude du métabolisme des cancéreux (métabolisme des corps azotés et des hydrates de carbone, glutathion de sang). J. de méd. de Lyon, 1930, 11, 507.
- Woodward, G. E., and Fry, E. G., The hyperglycaemia of cancer. Biochem. J., 1932, 26, 889.
- Andersen, P. E., Variations in the glucose tolerance test curves in patients with endometrial carcinoma. Acta radiol., 1952, 37, 178.
- Glicksman, A. S., Myers, W. P. L., and Rawson, R. W., Diabetes mellitus and carbohydrate metabolism in patients with cancer. M. Clin. North America, 1956, 40, 887.
- Nelson, N., A photometric adaptation of the Somogyi method for the determination of glucose. J. Biol. Chem., 1944, 153, 375.
- Somogyi, M., A new reagent for the determination of sugars. J. Biol. Chem., 1945, 160, 61.
- Taussky, H. H., and Shorr, E., A microcolorimetric method for the determination of inorganic phosphorus. J. Biol. Chem., 1953, 202, 675.
- 22. Conard, V., Franckson, J. R. M., Bastenie, P. A., Kestens, J., and Kovacs, L., Étude critique du triangle d'hyperglycémie intraveineux chez l'homme normal et détermination d'un "coefficient d'assimilation glucidique." Arch. internat. de pharmacodyn. et de therap., 1953, 93, 277.
- Amatuzio, D. S., Stutzman, F. L., Vanderbilt, M. J., and Nesbitt, S., Interpretation of the rapid intravenous glucose tolerance test in normal individuals and in mild diabetes mellitus. J. Clin. Invest., 1953, 32, 428.
- Duncan, L. J. P., The intravenous glucose tolerance test. Quart. J. Exper. Physiol., 1956, 41, 85.
- Greville, G. D., The intravenous glucose tolerance equation. Biochem. J., 1943, 37, 17.

- Lozner, E. L., Winkler, A. W., Taylor, F. H. L., and Peters, J. P., The intravenous glucose tolerance test. J. Clin. Invest., 1941, 20, 507.
- Jokipii, S. G., and Turpeinen, O., Kinetics of elimination of glucose from the blood during and after a continuous intravenous injection. J. Clin. Invest., 1954, 33, 452.
- Shreeve, W. W., Baker, N., Miller, M., Shipley, R. A., Incefy, G. E., and Craig, J. W., C³⁴ studies in carbohydrate metabolism. II. The oxidation of glucose in diabetic human subjects. Metabolism, 1956, 5, 22.
- 29. Dominguez, R., Kinetics of elimination, absorption and volume of distribution in the organism *in* Medical Physics, O. Glasser, Ed., Chicago, The Year Book Publishers, Inc., 1950, Vol. 2, p. 476.
- 30. Conard, V., Mesure de l'assimilation du glucose. Thesis, Brussels, Acta Medica Belgica, 1955, p. 54.
- 31. Wertheim, A. R., Eurman, G. H., and Kalinsky, H. J., Changes in serum in organic phosphorus during intravenous glucose tolerance tests: In patients with primary (essential) hypertension, other disease states, and in normal man. J. Clin. Invest., 1954, 33, 565.
- 32. Lazarus, S. S., Volk, B. W., Jacobi, M. J., and Gilady, M. Y., Absolute lymphocyte count and serum inorganic phosphorus after glucose administration in diabetic patients. Am. J. Clin. Path., 1952, 22, 127.
- 33. Pollack, H., Millet, R. F., Essex, H. E., Mann, F. C., and Bollman, J. L., Serum phosphate changes induced by injections of glucose into dogs under various conditions. Am. J. Physiol., 1934, 110, 117.
- Harrop, G. A., Jr., and Benedict, E. M., The participation of inorganic substances in carbohydrate metabolism. J. Biol. Chem., 1924, 59, 683.
- 35. Groen, J., Willebrands, A. F., Kamminga, C. E., Van Schothorst, H. K., and Godfried, E. G., Effects of glucose administration on the potassium and inorganic phosphate content of the blood serum and the electrocardiogram in normal individuals, and in non-diabetic patients. Acta med. Scandinav., 1952, 141, 352.
- 36. Cori, C. F., and Cori, G. T., The carbohydrate metabolism of tumors. II. Changes in the sugar, lactic acid, and CO₂-combining power of blood passing through a tumor. J. Biol. Chem., 1925, 65, 397.
- Greenstein, J. P., Biochemistry of Cancer. 2nd ed., New York, Academic Press, Inc., 1954, p. 507.
- Weber, G., and Cantero, A., Glucose-6-phosphatase activity in normal, precancerous and neoplastic tissues. Cancer Research, 1955, 15, 105.
- 39. Joslin, E. P., Root, H. F., White, P., and Marble, A., The Treatment of Diabetes Mellitus. 9th ed., Philadelphia, Lea & Febiger, 1952, p. 564.